{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:11:25Z","timestamp":1790230285265,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Celgene Corporation, Summit, NJ"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jid.2018.10.043","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T12:08:48Z","timestamp":1544011728000},"page":"1063-1072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["A Phase 2 Randomized Trial of Apremilast in\u00a0Patients with Atopic Dermatitis"],"prefix":"10.1016","volume":"139","author":[{"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Poulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei-Chi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeriel D.","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilam","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayte","family":"Suarez-Farinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Nograles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2018.10.043_bib1","unstructured":"Adams M, Horan G, Schafer PH. Apremilast regulates human keratinocyte gene expression in\u00a0vitro and reduces antigen-driven dermatitis in\u00a0vivo. Poster presented at: Congress of the European Academy of Dermatology and Venereology. October 7\u201311, 2015; Copenhagen, Denmark."},{"key":"10.1016\/j.jid.2018.10.043_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2018.10.043_bib3","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"4 Suppl","key":"10.1016\/j.jid.2018.10.043_bib4","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2018.10.043_bib5","series-title":"Otezla[package insert]","author":"Celgene","year":"2017"},{"key":"10.1016\/j.jid.2018.10.043_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for \u2265156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib7","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A\u00a0phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jid.2018.10.043_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaip.2014.03.006","article-title":"Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications","volume":"2","author":"Czarnowicki","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jid.2018.10.043_bib9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2018.10.043_bib10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib12","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","article-title":"Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin","volume":"138","author":"Esaki","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2018.10.043_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of TH2\/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2018.10.043_bib14","first-page":"888","article-title":"Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study","volume":"12","author":"Gottlieb","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?","volume":"48","author":"Guttman-Yassky","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jid.2018.10.043_bib16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/exd.13336","article-title":"Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment","volume":"27","author":"Guttman-Yassky","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib17","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2011.01.054","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014part II: immune cell subsets and therapeutic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2018.10.043_bib18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2133.2002.05006.x","article-title":"Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients","volume":"147","author":"Hanifin","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib19","first-page":"32","article-title":"Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study","volume":"8","author":"Jensterle","year":"2015","journal-title":"J\u00a0Ovarian Res"},{"key":"10.1016\/j.jid.2018.10.043_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.140647","article-title":"Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis","volume":"42","author":"Kavanaugh","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jid.2018.10.043_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000245677","article-title":"Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis","volume":"195","author":"Kunz","year":"1997","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2018.10.043_bib22","first-page":"250","article-title":"Treatment of atopic dermatitis in the United States: analysis of data from the National Ambulatory Medical Care Survey","volume":"16","author":"McGregor","year":"2017","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"Suppl. 10","key":"10.1016\/j.jid.2018.10.043_bib23","first-page":"604","article-title":"Consistent safety profile with up to 4 years of apremilast treatment: analysis of data from 1,493 subjects with psoriatic arthritis in 3 large, phase III, long-term studies [abstract]","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2018.10.043_bib24","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2018.10.043_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9843","key":"10.1016\/j.jid.2018.10.043_bib26","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2018.10.043_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1])","volume":"73","author":"Papp","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0625.2007.00634.x","article-title":"Increased expression of CC chemokine ligand 18 in extrinsic atopic dermatitis patients","volume":"17","author":"Park","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/exd.12034","article-title":"Insight into newly discovered innate immune modulation in atopic dermatitis","volume":"22","author":"Park","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib30","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib31","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1590\/S0365-05962012000500010","article-title":"Bacterial skin colonization and infections in patients with atopic dermatitis","volume":"87","author":"Petry","year":"2012","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib32","series-title":"Eucrisa [package insert]","author":"Pfizer","year":"2017"},{"key":"10.1016\/j.jid.2018.10.043_bib33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept, and placebo, in patients with moderate to severe plaque psoriasis: 52-week results from a phase 3b, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2018.10.043_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaci.2017.09.033","article-title":"Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data","volume":"141","author":"Roekevisch","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2018.10.043_bib35","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","article-title":"A\u00a0pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults","volume":"148","author":"Samrao","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib36","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.jid.2018.10.043_bib37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.10.043_bib38","first-page":"397","article-title":"A\u00a0review of patient adherence to topical therapies for treatment of atopic dermatitis","volume":"96","author":"Snyder","year":"2015","journal-title":"Cutis"},{"key":"10.1016\/j.jid.2018.10.043_bib39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Suarez-Farinas","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2018.10.043_bib40","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Suarez-Farinas","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2018.10.043_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00005-015-0344-z","article-title":"The role of IL-17 and Th17 lymphocytes in autoimmune diseases","volume":"63","author":"Tabarkiewicz","year":"2015","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.jid.2018.10.043_bib42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2011.05.042","article-title":"Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response","volume":"128","author":"Tintle","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2018.10.043_bib43","first-page":"341","article-title":"A\u00a0phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis","volume":"11","author":"Volf","year":"2012","journal-title":"J\u00a0Drugs Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18329051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18329051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T21:38:29Z","timestamp":1720820309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X18329051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0022202X18329051"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2018.10.043","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2 Randomized Trial of Apremilast in\u00a0Patients with Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2018.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}